Remove 2027 Remove Food and Drug Administration Remove Sales
article thumbnail

Potential blockbuster drugs to watch in 2023

European Pharmaceutical Review

Clarivate Plc has released its Drugs to Watch 2023 report — among 70 of the drugs highlighted, including potential blockbuster drugs, the majority were revealed to be personalised medicines. The report offers predictive analysis of drugs entering the market or launching key indications in 2023.

article thumbnail

Treatment options for Crohn’s disease expand after Rinvoq approval

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Merck obtains favourable US court ruling on sitagliptin patent lawsuit

Pharmaceutical Technology

It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. Viatris is seeking approval from the US Food and Drug Administration (FDA) to market Januvia and Janumet’s generic versions in the country. The suit involved two Merck patents.

article thumbnail

Moving towards oral delivery of biologics

European Pharmaceutical Review

Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics.

article thumbnail

Article Reviews the Evolution of Arthroscopy from its Invention in 1912 to the Dawn of the Wireless ArthroFree™ Era

Legacy MEDSearch

BN by 2027. Developed by Cleveland-based Lazurite Holdings LLC, ArthroFree recently became the first wireless camera for arthroscopy and general endoscopy to receive market clearance from the Food and Drug Administration. This system has helped propel the arthroscopic market to an expected US $16.3

article thumbnail

OpSens Announces FDA Clearance for the SavvyWire™ for Use in Transcatheter Aortic Valve Replacement (TAVR) Procedures

Legacy MEDSearch

Food & Drug Administration (“FDA”) for the SavvyWire (“SavvyWire”), its new guidewire for transcatheter aortic valve replacement procedures, or TAVR. The global TAVR market is currently estimated at over 200,000 procedures and is expected to reach 400,000 in 2027. OpSens Inc. , About OpSens Inc.

FDA 52
article thumbnail

High biologics demand spurs need for greater contract manufacturing

Pharmaceutical Technology

These attributes make some biologic drugs, especially monoclonal antibodies more specific and targeted in their treatment. With new drugs on the market, companies are now looking for ways to manufacture recently approved biologics, and countries are racing to claim their corner – or maintain their decades-old market share.